GIST
SSG XXII
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study
Ansprechpartner:
Studiensekretariat:
Herr OA Prof. Dr. med. M. Venerito
Frau I. Gromeier/ Frau C. Glaubitz
Telefon: 0391/ 67 21512